Viking Therapeutics Inc (VKTX) was Reiterated by Laidlaw to “Buy” while Lowering the Price Target of the company shares to $ 10 from a previous price target of $20 . Laidlaw advised their investors in a research report released on Aug 11, 2016.
Many Wall Street Analysts have commented on Viking Therapeutics Inc. Maxim Group Initiated Viking Therapeutics Inc on May 24, 2016 to “Buy”, Price Target of the shares are set at $5.
Viking Therapeutics Inc closed down -0.04 points or -2.86% at $1.36 with 75,741 shares getting traded on Monday. Post opening the session at $1.4, the shares hit an intraday low of $1.34 and an intraday high of $1.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 13, 2016, Matthew W Foehr (director) purchased 20,000 shares at $1.24 per share price.
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211 which is an orally available drug candidate under a Phase II clinical trial. Its second clinical program is focused on the development of molecule agonists of the thyroid receptor beta (TRB) for adrenoleukodystrophy (ALD) and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH). The Company is also engaged in developing VK2809 and VK0214 for the treatment and potential prophylaxis of ALD. Its VK0612 is an orally available Phase IIb-ready drug candidate for type 2 diabetes. The Company’s preclinical programs are focused on identifying erythropoietin receptor (EPOR) agonists for the treatment of anemia and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1 (DGAT-1) for the treatment of obesity and dyslipidemia.